Aegle Therapeutics is conducting a Phase 1/2A, non-randomized, multi-center, ascending dose, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
AGLE-102 is a topical agent composed of native extracellular vesicles (EVs) derived from donor mesenchymal stem cells (MSCs) - special cells in your body that can act like repair crews and have the power to help fix and regenerate different tissues.
The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with RDEB.
Compensation to support travel to the clinical trial sites will be offered.
Visit clinicaltrials.gov for a full list of inclusion and exclusion criteria.
If you have questions regarding the RDEB AGLE-102 Clinical Trial, or if you are interested in participating, please contact the study coordinator for each trial site:
All three sites are open for adult enrollment. Children's Hospital of Philadelphia (CHOP) and Phoenix Children's Hospital also have IRB approval to treat patients 6 months of age and older. Travel compensation will be provided.
See the AGLE-102 informational brochure
